Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGLE Aeglea BioTherapeutics		$11.47	$2.66 ▼ $32.75	$48.64M	2.57	95,409 shs	43,300 shs
ELDN Eledon Pharmaceuticals	$3.15	$3.09	$2.30 ▼ $5.54	$188.63M	0.08	273,122 shs	135,600 shs
OMER Omeros	$3.14 -0.9%	$6.19	$2.97 ▼ $13.60	$183.98M	2.42	671,349 shs	1.08 million shs
SLS SELLAS Life Sciences Group	$1.78 -7.8%	$1.41	$0.77 ▼ $2.12	$177.60M	2.34	1.52 million shs	2.40 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGLE Aeglea BioTherapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ELDN Eledon Pharmaceuticals	0.00%	0.00%	-3.96%	-22.79%	+22.09%
OMER Omeros	-0.95%	+0.96%	-56.81%	-63.15%	-5.28%
SLS SELLAS Life Sciences Group	-7.77%	+4.71%	+26.24%	+56.14%	+28.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGLE Aeglea BioTherapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	2.7279 of 5 stars	3.5	4.0	0.0	0.0	3.6	1.7	0.0
OMER Omeros	3.6631 of 5 stars	3.4	0.0	0.0	4.4	3.1	1.7	0.6
SLS SELLAS Life Sciences Group	0.4672 of 5 stars	0.0	1.0	0.0	0.0	4.4	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGLE Aeglea BioTherapeutics	0.00	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	3.00	Buy	$12.50	296.83% Upside
OMER Omeros	2.80	Moderate Buy	$22.50	616.56% Upside
SLS SELLAS Life Sciences Group	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AGLE, SLS, ELDN, and OMER Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	OMER Omeros	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/13/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
5/7/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
4/11/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
4/1/2025	OMER Omeros	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/1/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
3/21/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGLE Aeglea BioTherapeutics	$2.33M	0.00	N/A	N/A	($60.61) per share	0.00
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$0.30 per share	N/A
OMER Omeros	N/A	N/A	N/A	N/A	($0.40) per share	N/A
SLS SELLAS Life Sciences Group	$1M	177.60	N/A	N/A	($0.25) per share	-7.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGLE Aeglea BioTherapeutics	-$83.82M	-$75.59	N/A	N/A	N/A	-22,195.36%	-132.05%	-146.87%	N/A
ELDN Eledon Pharmaceuticals	-$116.54M	-$2.10	N/A	N/A	N/A	N/A	-189.99%	-28.17%	N/A
OMER Omeros	-$117.81M	-$2.65	N/A	N/A	N/A	N/A	N/A	-49.92%	8/6/2025 (Estimated)
SLS SELLAS Life Sciences Group	-$37.34M	-$0.38	N/A	N/A	N/A	N/A	-629.46%	-178.65%	8/12/2025 (Estimated)

Latest AGLE, SLS, ELDN, and OMER Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	OMER Omeros	-$0.60	-$0.65	-$0.05	-$0.58	$0.40 million	N/A
5/14/2025	Q1 2025	ELDN Eledon Pharmaceuticals	-$0.28	-$0.08	+$0.20	-$0.08	N/A	N/A
5/13/2025	Q1 2025	SLS SELLAS Life Sciences Group	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A
3/31/2025	Q4 2024	OMER Omeros	-$0.71	-$0.63	+$0.08	-$0.54	$0.40 million	N/A
3/20/2025	Q4 2024	ELDN Eledon Pharmaceuticals	-$0.32	-$0.64	-$0.32	-$0.64	N/A	N/A
3/20/2025	Q4 2024	SLS SELLAS Life Sciences Group	-$0.1067	-$0.08	+$0.0267	-$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGLE Aeglea BioTherapeutics	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGLE Aeglea BioTherapeutics	N/A	4.59	4.59
ELDN Eledon Pharmaceuticals	N/A	6.53	6.53
OMER Omeros	N/A	2.96	2.96
SLS SELLAS Life Sciences Group	N/A	2.26	2.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGLE Aeglea BioTherapeutics	N/A
ELDN Eledon Pharmaceuticals	56.77%
OMER Omeros	48.79%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
AGLE Aeglea BioTherapeutics	6.60%
ELDN Eledon Pharmaceuticals	12.30%
OMER Omeros	12.30%
SLS SELLAS Life Sciences Group	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGLE Aeglea BioTherapeutics	69	4.05 million	3.78 million	Optionable
ELDN Eledon Pharmaceuticals	10	59.88 million	52.75 million	Optionable
OMER Omeros	210	58.59 million	50.82 million	Optionable
SLS SELLAS Life Sciences Group	10	99.78 million	69.54 million	Not Optionable

AGLE, SLS, ELDN, and OMER Headlines

Recent News About These Companies

594,919 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Bought by Brooklyn FI LLC

May 28 at 6:12 AM | marketbeat.com

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 20, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Common Stock

May 16, 2025 | fxempire.com

Sellas doses first paediatric subject with AML in Phase II trial of SLS009

May 16, 2025 | msn.com

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | finanznachrichten.de

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | globenewswire.com

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025 | globenewswire.com

SELLAS Life Sciences Group (SLS) to Release Earnings on Tuesday

May 8, 2025 | marketbeat.com

Anson Funds Management LP Has $1.24 Million Holdings in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)

May 5, 2025 | marketbeat.com

SELLAS Life Sciences Group, Inc. Presents Promising Preclinical Data on SLS009 for TP53 Mutated Acute Myeloid Leukemia at AACR 2025

April 28, 2025 | quiverquant.com

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

April 28, 2025 | globenewswire.com

Why SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 8.95%

April 26, 2025 | aaii.com

SELLAS Life Sciences Group, Inc. to Present Preclinical Efficacy Data for SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025 Annual Meeting

April 23, 2025 | quiverquant.com

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

April 23, 2025 | globenewswire.com

Sellas Life Sciences announces OS data in Cohort 3 from Phase 2 SLS009 trial

April 9, 2025 | markets.businessinsider.com

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

April 8, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Common Stock (SLS) Insider Activity

March 30, 2025 | nasdaq.com

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

March 21, 2025 | finanznachrichten.de

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

March 20, 2025 | globenewswire.com

Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment

February 21, 2025 | msn.com

SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

February 20, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
3 Retail Stocks That Desperately Need a Tariff Break
By Chris Markoch | April 30, 2025
View 3 Retail Stocks That Desperately Need a Tariff Break

AGLE, SLS, ELDN, and OMER Company Descriptions

Aeglea BioTherapeutics NASDAQ:AGLE

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Eledon Pharmaceuticals NASDAQ:ELDN

$3.15 0.00 (0.00%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$3.15 0.00 (0.00%)

As of 05/28/2025 04:04 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Omeros NASDAQ:OMER

$3.14 -0.03 (-0.95%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$3.23 +0.09 (+2.87%)

As of 05/28/2025 06:58 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

SELLAS Life Sciences Group NASDAQ:SLS

$1.78 -0.15 (-7.77%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$1.82 +0.03 (+1.97%)

As of 05/28/2025 07:59 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time